Summary: The cellular function of amylin is investigated in L6 myocytes, a tat skeletal muscle cell line. Both rat amylin and human amylin-amide acutely cause a dose-dependent increase in cyclic AMP formation in L6 myocytes. 100 r&I tat amylin stimulates intracellular cyclic AMP concentrations 12-fold, whereas human amylin-amide at this concentration causes only a 2-fold increase. Up to 10 mM human amylin has no effect on cyclic AMP levels. Rat calcitonin generelated peptide (CGRP) is more potent than amylin, causing a 60-fold increase over basal at 1 nM, with an EC50 value of 0.2 nM. The CGRP receptor antagonist, human CGRPg37 (hCGRPs-37), completely blocks the stimulatory effect of both tat amylin and human amylin-amide on cyclic AMP production. [*qCGRP binds specifically to a membrane fraction prepared from L6 myocytes with a Kd = 2.1 nM and Bmax = 144 fmol/mg protein. Amylin is the major peptide component of the islet amyloid deposits that occur in over 90% of patients with Non-Insulin Dependent Diabetes Mellitus (NIDDM) and more than 75% of diabetic Pima Indians (1,2). Amylin has been isolated and characterized as a 37 amino acid peptide that is produced by pancreatic D-cells, co-packaged with insulin in secretory granules and co-secreted into the sinusoidal space. Human amylin exhibits almost 50 percent sequence identity to calcitonin gene-related peptide (CGRP), a neuropeptide hormone that is distributed widely in the nervous system and peripheral organs (3-5). Some evidence suggests that both amylin and CGRP may be involved in the pathogenesis of insulin resistance in NIDDM. Both peptides have been reported to lower basal and insulin-stimulated glycogen synthesis in skeletal muscle, as well as cause an acute
L6 myocytes were originally obtained from the American Type CultureCollection (Rockville, MD) and were maintained in DMEM supplemented with 10% fetal bovine serum. The activity of adenylyl cyclase was assayed by measuring the accumulation of [JHlcyclic AMP in cells pre-labelled with [jH] adenine. Cells grown to confluence in 12-well plates, were labeled for 3 h with 0.5 uCi [jH]adenine in 0.5 ml of growth medium. After labeling, the cells were washed with minimal essential medium supplemented with 20 mM HEPES, 1 mM 3-isobutyl-I-methyl-xanthine and 0.1% bovine serum albumin. The cells were then treated with various conditions for 10 min at room temperature. The incubation was terminated by aspiration of medium and addition of 0.3 ml 0.1 M HCl containing 1 mM cyclic AMP. Total [3H]cyclic AMP was determined after sequential chromatography on Dowex and alumina columns (13).
Preparation of Plasma Membranes:
Crude plasma membranes of L6 myocytes were prepared from cells grown in 150 mm culture plates. Cells were washed with ice-cold phosphate buffered saline and subsequently swollen in 5 mM Tris buffer supplemented with EDTA, 10 uM leupeptin, 10 uM pepstatin A, 10 uM bacitracin and 100 uM phenylmethylsulfonyl fluoride (PMSF). Cells were removed from the plates by scraping with a rubber policeman and kept on ice for 15 min, followed by disruption with a Brinkman Polytron PT-10 at setting 7 for 30 sec. Following sonication for 30 set, the homogenate was centrifuged at 50,000 xgfor 30 min and the resulting pellets were resuspended in 50 mM Tris-HCl containing 100 mM NaCl, 10 mM MgC12, 100 mM PMSF, 10 mM leupeptin, 10 mM pepstatin A and 10 mM aprotinin.
In some experiments, plasma membranes were purified from fresh livers obtained from adult male Sprague-Dawley rats (250-350 g) as previously described (14). Briefly, livers were homogenized in 1 mM sodium bicarbonate buffer, pH 8.0, containing 10 mM EGTA, 5 mM EDTA, 100 JIM PMSF, 10 uM leupeptin, 10 PM pepstatin A and 10 uM aprotinin. The liver homogenate was centrifuged for 10 min at 400 x g, and the pellets were resuspended in 70% (wt/vol) sucrose to achieve a tinal sucrose concentration of44% (wt/vol). Fifteen milliliters of40% (wt/vol) sucrose was layered over 22 ml of the homogenate, and the preparation was centrifuged for 2 h at 122,000 x g. The purified membranes were washed twice with phosphate buffered saline, pH 7.4, at 4'C. Plasma membranes from rat brain were prepared in a similar fashion, and the pellets resuspended in 50 mM Tris-HCl buffer containing 100 mM NaCl and 10 mM MgC12. Protein was assayed by the Bio-Rad dye-binding method using bovine serum albumin as standard. Membranes were stored in aliquots at -70-C for up to 3 weeks.
Receptor binding assay: Radioligand binding to plasma membranes was assayed as described (6, 15, 16) with slight modification. Membranes were incubated for 2 hat 4-C in a final volume of 0.5 ml consisting of 50 mM Tris-HCl buffer, 100 n&l NaCl, 10 mM MgC12, 1% bovine serum albumin, 100 l.tM bacitracin, 58 pM [t*sI]CGRP or 200 pM [125I]amylin and various concentrations of unlabeled ligands. Bound [125I]peptide was separated from free by rapid filtration through Whatman GFK glass filter sheets presoaked in 50 mM Tris-HCl buffer, pH 7.7, containing 0.5% of polyethylenimine (16) and 100 urn bacitracin using a Brandel 48 R cell Vol. 177, No. 2, 1991 BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS harvester. The filters were washed three times with 4 ml of Tris buffer and then counted for gamma radioactivity.
Data analysis: Saturation binding analysis was performed using the LIGAND program ( 17). IC5o and EC50 values were calculated by weighted nonlinear regression curve-fitting to the massaction equation.
Results and Discussion
Amylin and CGRP increase cyclic AMP formation in L6 myocytes. One of the mechanisms by which counter-regulatory hormones inhibit the insulin-dependent increase in glycogen synthesis in skeletal muscles is through elevation of cyclic AMP levels. To determine if amylin could modulate cyclic AMP, levels of cyclic AMP were assayed in L6 myocytes exposed to amylin or CGRP. CGRP acutely caused a large dose-dependent increase in intracellular cyclic AMP levels in L6 myocytes. Over a 60-fold stimulation was observed with 1nM CGRP, with an EC50 value of 0.2 nM (Fig. 1 ). Both rat amylin and human amylin-amide similarly caused a dosedependent increase in cyclic AMP levels, albeit at much higher concentrations. In these experiments, concentrations of peptides greater than 10 PM could not be used, due to solubility problems, so we were unable to explore whether the effect of amylin was saturable. Nevertheless, it is Iikely that both of the amylin peptides may be full agonists. Further, it is clear that rat amylin is approximately 10 fold more potent than human amylin-amide, whereas human amylin at concentrations up to 10 pM was ineffective in raising cyclic AMP levels. These results parallel the predicted order of potency of amylin peptides studied in other systems (7, 10, 11, 18, 19 Pia. 2. The CGRP receptor antagonist, CGRPs-37, attenuates the stimulatory effect of amylin on CAMP levels. After 5 min incubation with increasing concentmtion of human CGPPg-37, L6 myocytes were stimulated by either 10 nM rat CGRP, 1 pM rat amylin or 10 pM human amylin-amide for 10 min at room temperature. Results are presented as the means + standard deviation oftriplicate determinations, repeated in three separate experiments.
cyclic AMP in L6 myocytes. hCGRP,-,, inhibited cyclic AMP formation in L6 myocytes stimulated by CGRP or by rat amylin and human amylin-amide in a dose-dependent manner (Fig.   2 ). 1 mM hCGRP&-37 caused a 94% inhibition of the stimulatory effect of 10 nM CGRP and a 90-98% inhibition ofthe stimulation caused by 1 JJM rat amylin or 10 pM human amylin-amide.
Rat amylin displaces
[125I]CGRP specific binding.
[125IlCGRP specifically bound to membranes prepared from L6 myocytes in a saturable manner, yielding a Kd of 2.1 nM and Bmax of 144 fmol/mg protein. The specificity of [125IJCGRP binding to L6 myocytes was evaluated by competition binding assays using rat CGRP, hCGRPg-37 and rat amylin (Fig. 3A) .
Increasing concentrations of these peptides inhibited [ *2511CGRP binding to plasma membranes of L6 myocytes in a dose-dependent fashion. Analysis of these data revealed that hCGRPg-37 was almost as effective as rat CGRP in competing for [ 1251]CGRP binding, yielding Ki values of 0.9 nM and 1.5 nM, respectively. Interestingly, rat amylin also displaced the binding of [l*SI]CGRP withaKiof91 nM.
Binding of [125I]CGRP to plasma membranes prepared from rat liver (Fig. 3B ) and brain ( Fig. 3C) [ t*5I]CGRP binding was assayed in plasma membranes prepared from L6 myocytes (A), liver(B) or brain(C), in the presence of rat CGRP, rat amylin or human CGRP8.37. Plasma membranes were incubated for 2 h at 4-C with 49-58 pM [ 1*5I]CGRP in the presence of varying concentrations of the peptides as indicated. Data are expressed as the percentage of maximal binding in absence of unlabeled peptides. Values are means f standard deviations of triplicate determinations, repeated in three separate experiments.
that nanomolar concentrations of amylin are biologically active in L6 myocytes is consistent with previous reports demonstrating that similar concentrations of amylin inhibit insulin-stimulated glycogen synthesis and glucose uptake in soleus muscle (7, 10, 11, 18, 19) . While the physiological role of amylin remains to be elucidated, it is apparent that its reported actions are likely to be mediated through CGRP receptors (20) . This further suggests that amylin may share some of the actions of CGRP and have unappreciated effects on the vasdulature and central nervous system.
